Ovarian cancer staging: time for a closer look?
DR Spriggs and S Makhija
JCO Aug 1 1998: 2577–2578. [PDF]
Adjuvant chest wall and nodal irradiation: maximize cure, minimize late cardiac toxicity
RR Kuske
JCO Aug 1 1998: 2579–2582. [PDF]
	BAX protein expression and clinical outcome in epithelial ovarian cancer [published erratum appears in J Clin Oncol 1998 Sep;16(9):3211]
	YT Tai, S Lee, E Niloff, C Weisman, T Strobel, and SA Cannistra
	JCO Aug 1 1998: 2583–2590. [Abstract] [PDF]
	Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer
	M Anttila, VM Kosma, H Ji, X Wei-Ling, J Puolakka, M Juhola, S Saarikoski, and K Syrjanen
	JCO Aug 1 1998: 2591–2600. [Abstract] [PDF]
	Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer
	A Weaver, J Chang, E Wrigley, E de Wynter, PJ Woll, M Lind, B Jenkins, C Gill, PM Wilkinson, R Pettengell, JA Radford, CD Collins, TM Dexter, NG Testa, and D Crowther
	JCO Aug 1 1998: 2601–2612. [Abstract] [PDF]
	Human papillomavirus genotype as a major determinant of the course of cervical cancer
	I Lombard, A Vincent-Salomon, P Validire, B Zafrani, A de la Rochefordiere, K Clough, M Favre, P Pouillart, and X Sastre-Garau
	JCO Aug 1 1998: 2613–2619. [Abstract] [PDF]
	Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study
	M Markman, MF Brady, NM Spirtos, P Hanjani, and SC Rubin
	JCO Aug 1 1998: 2620–2624. [Abstract] [PDF]
	Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries
	LF Paszat, WJ Mackillop, PA Groome, C Boyd, K Schulze, and E Holowaty
	JCO Aug 1 1998: 2625–2631. [Abstract] [PDF]
	Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
	PJ Bostick, S Chatterjee, DD Chi, KT Huynh, AE Giuliano, R Cote, and DS Hoon
	JCO Aug 1 1998: 2632–2640. [Abstract] [PDF]
	Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort
	MA Levesque, H Yu, GM Clark, and EP Diamandis
	JCO Aug 1 1998: 2641–2650. [Abstract] [PDF]
	Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group
	MN Levine, VH Bramwell, KI Pritchard, BD Norris, LE Shepherd, H Abu-Zahra, B Findlay, D Warr, D Bowman, J Myles, A Arnold, T Vandenberg, R MacKenzie, J Robert, J Ottaway, M Burnell, CK Williams, and D Tu
	JCO Aug 1 1998: 2651–2658. [Abstract] [PDF]
	Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
	MD Pegram, A Lipton, DF Hayes, BL Weber, JM Baselga, D Tripathy, D Baly, SA Baughman, T Twaddell, JA Glaspy, and DJ Slamon
	JCO Aug 1 1998: 2659–2671. [Abstract] [PDF]
	Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
	B Fisher, J Bryant, N Wolmark, E Mamounas, A Brown, ER Fisher, DL Wickerham, M Begovic, A DeCillis, A Robidoux, RG Margolese, AB Cruz, Jr, JL Hoehn, AW Lees, NV Dimitrov, and HD Bear
	JCO Aug 1 1998: 2672–2685. [Abstract] [PDF]
	Aging, progression, and phenotype in breast cancer
	R Heimann and S Hellman
	JCO Aug 1 1998: 2686–2692. [Abstract] [PDF]
	Infiltrating ductal carcinoma of the breast: the survival impact of race
	MJ Edwards, JW Gamel, WP Vaughan, and WR Wrightson
	JCO Aug 1 1998: 2693–2699. [Abstract] [PDF]
	Routine use of granulocyte colony-stimulating factor is not cost- effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model
	C Chouaid, L Bassinet, C Fuhrman, I Monnet, and B Housset
	JCO Aug 1 1998: 2700–2707. [Abstract] [PDF]
	Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma
	VC Tjan-Heijnen, B Biesma, J Festen, TA Splinter, A Cox, DJ Wagener, and PE Postmus
	JCO Aug 1 1998: 2708–2714. [Abstract] [PDF]
	Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival
	MS Kies, DJ Haraf, I Athanasiadis, M Kozloff, B Mittal, H Pelzer, AW Rademaker, B Wenig, RR Weichselbaum, and EE Vokes
	JCO Aug 1 1998: 2715–2721. [Abstract] [PDF]
	Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial
	DF Bajorin, JA McCaffrey, S Hilton, M Mazumdar, WK Kelly, HI Scher, J Spicer, H Herr, and G Higgins
	JCO Aug 1 1998: 2722–2727. [Abstract] [PDF]
	Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d'Immunotherapie
	A Ravaud, B Audhuy, F Gomez, B Escudier, T Lesimple, C Chevreau, JY Douillard, A Caty, L Geoffrois, JM Ferrero, C Linassier, M Drevon, and S Negrier
	JCO Aug 1 1998: 2728–2732. [Abstract] [PDF]
	Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology
	HR Rosen, G Jatzko, S Repse, S Potrc, H Neudorfer, P Sandbichler, J Zacherl, H Rabl, P Holzberger, P Lisborg, and M Czeijka
	JCO Aug 1 1998: 2733–2738. [Abstract] [PDF]
	Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers
	Y Becouarn, M Ychou, M Ducreux, C Borel, F Bertheault-Cvitkovic, JF Seitz, S Nasca, TD Nguyen, B Paillot, JL Raoul, J Duffour, A Fandi, G Dupont-Andre, and P Rougier
	JCO Aug 1 1998: 2739–2744. [Abstract] [PDF]
	Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment
	F Saliba, R Hagipantelli, JL Misset, G Bastian, G Vassal, M Bonnay, P Herait, C Cote, M Mahjoubi, D Mignard, and E Cvitkovic
	JCO Aug 1 1998: 2745–2751. [Abstract] [PDF]
	Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer
	BD Curti, AC Ochoa, GC Powers, WC Kopp, WG Alvord, JE Janik, BL Gause, B Dunn, MS Kopreski, R Fenton, A Zea, C Dansky-Ullmann, S Strobl, L Harvey, E Nelson, M Sznol, and DL Longo
	JCO Aug 1 1998: 2752–2760. [Abstract] [PDF]
	Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer
	CV Christodoulou, DR Ferry, DW Fyfe, A Young, J Doran, TM Sheehan, A Eliopoulos, K Hale, J Baumgart, G Sass, and DJ Kerr
	JCO Aug 1 1998: 2761–2769. [Abstract] [PDF]
	Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies
	MA Villalona-Calero, SD Baker, L Hammond, C Aylesworth, SG Eckhardt, M Kraynak, R Fram, S Fischkoff, R Velagapudi, D Toppmeyer, B Razvillas, K Jakimowicz, DD Von Hoff, and E Rowinsky
	JCO Aug 1 1998: 2770–2779. [Abstract] [PDF]
	New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
	JO Armitage and DD Weisenburger
	JCO Aug 1 1998: 2780–2795. [Abstract] [PDF]
	VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group
	G Santini, L Salvagno, P Leoni, T Chisesi, C De Souza, MR Sertoli, A Rubagotti, AM Congiu, R Centurioni, A Olivieri, L Tedeschi, M Vespignani, S Nati, M Soracco, A Porcellini, A Contu, C Guarnaccia, N Pescosta, I Majolino, M Spriano, R Vimercati, E Rossi, G Zambaldi, L Mangoni, and V Rizzoli
	JCO Aug 1 1998: 2796–2802. [Abstract] [PDF]
	Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution
	L Fouillard, JP Laporte, M Labopin, S Lesage, F Isnard, L Douay, M Lopez, M Aoudjhane, P Zunic, N Cheron, J Stachowiak, MP Lemonnier, G Andreu, Y Belkacemi, MP Noel-Walter, P Morel, P Fenaux, JP Jouet, F Bauters, A Najman, and NC Gorin
	JCO Aug 1 1998: 2803–2816. [Abstract] [PDF]
	Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
	IF Khouri, M Keating, M Korbling, D Przepiorka, P Anderlini, S O'Brien, S Giralt, C Ippoliti, B von Wolff, J Gajewski, M Donato, D Claxton, N Ueno, B Andersson, A Gee, and R Champlin
	JCO Aug 1 1998: 2817–2824. [Abstract] [PDF]
	Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
	P McLaughlin, AJ Grillo-Lopez, BK Link, R Levy, MS Czuczman, ME Williams, MR Heyman, I Bence-Bruckler, CA White, F Cabanillas, V Jain, AD Ho, J Lister, K Wey, D Shen, and BK Dallaire
	JCO Aug 1 1998: 2825–2833. [Abstract] [PDF]
	Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma
	B Zee, B Cole, T Li, G Browman, K James, D Johnston, D Sugano, and J Pater
	JCO Aug 1 1998: 2834–2839. [Abstract] [PDF]
	Consolidation therapy with antimetabolite-based therapy in standard- risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study
	MB Harris, JJ Shuster, DJ Pullen, MJ Borowitz, AJ Carroll, FG Behm, and VJ Land
	JCO Aug 1 1998: 2840–2847. [Abstract] [PDF]
	Second malignancies in patients treated for childhood acute lymphoblastic leukemia
	VM Kimball Dalton, RD Gelber, F Li, MJ Donnelly, NJ Tarbell, and SE Sallan
	JCO Aug 1 1998: 2848–2853. [Abstract] [PDF]
	Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study
	JJ Shuster, P Wacker, J Pullen, J Humbert, VJ Land, DH Mahoney, Jr, S Lauer, AT Look, MJ Borowitz, AJ Carroll, and B Camitta
	JCO Aug 1 1998: 2854–2863. [Abstract] [PDF]
	Programs for adult survivors of childhood cancer
	KC Oeffinger, DA Eshelman, GE Tomlinson, and GR Buchanan
	JCO Aug 1 1998: 2864–2867. [Abstract] [PDF]
	Decision-making about breast cancer susceptibility testing: how similar are the attitudes of physicians, nurse practitioners, and at-risk women?
	G Geller, BA Bernhardt, T Doksum, KJ Helzlsouer, P Wilcox, and NA Holtzman
	JCO Aug 1 1998: 2868–2876. [Abstract] [PDF]
	Uracil-tegafur in gastric carcinoma: a comprehensive review
	H Takiuchi and JA Ajani
	JCO Aug 1 1998: 2877–2885. [Abstract] [PDF]
Postmastectomy radiotherapy: questions for the twenty-first century [published erratum appears in J Clin Oncol 1998 Sep;16(9):3211]
A Recht, H Bartelink, A Fourquet, B Fowble, BG Haffty, JR Harris, J Kurtz, B McCormick, IA Olivotto, L Rutqvist, LJ Solin, and J Yarnold
JCO Aug 1 1998: 2886–2889. [PDF]
Dermatomyositis and breast cancer
S Daryanani
JCO Aug 1 1998: 2890–2891. [PDF]
Letrozole for advanced breast cancer
G Hoctin-Boes, R Yates, and M Steinberg
JCO Aug 1 1998: 2892–2893. [PDF]
XRT for stage IV Hodgkin's disease? Less chaff please
JJ Beitler
JCO Aug 1 1998: 2893a. [PDF]
Combined modality in advanced Hodgkin's disease
M Baumann, T Herrmann, and HD Thames
JCO Aug 1 1998: 2893b–2894. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.